Experimental therapy of malignant mesothelioma: New perspectives from anti-angiogenic treatments

Alfonso Catalano, Walter Gianni, Antonio Procopio

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We reviewed the published literature of clinical studies in malignant mesothelioma (MM), including phase II as well as older single-agent and combination chemotherapy trials with more than 15 patients. While response rates exceeding 30% have been achieved with established cytotoxic drugs in MM therapy, novel chemotherapeutic agents and their combinations appear more promising. This applies especially to the anti-metabolites (i.e. pemetrexed) that produced response rates of up to 45% in combination with platinum compounds. Moreover, agents targeting novel proliferative and survival pathways in MM are developed to improve treatment outcomes. Here, we focused on the role of several angiogenic growth factors in MM biology and the data of MM-oriented studies on angiostatic agents tested in a phase I-II trial. It seems likely that no single treatment modality will be effective by itself. Studies that use combinations of the newer agents, including angiostatic drugs, with chemotherapy, should be conducted.

Original languageEnglish
Pages (from-to)101-109
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume50
Issue number2
DOIs
Publication statusPublished - May 2004

Fingerprint

Investigational Therapies
Angiogenesis Inhibitors
Pemetrexed
Platinum Compounds
Therapeutics
Angiogenesis Inducing Agents
Combination Drug Therapy
Pharmaceutical Preparations
Intercellular Signaling Peptides and Proteins
Malignant Mesothelioma
Drug Therapy
Survival

Keywords

  • Anti-angiogenic agents
  • Mesothelioma
  • Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Experimental therapy of malignant mesothelioma : New perspectives from anti-angiogenic treatments. / Catalano, Alfonso; Gianni, Walter; Procopio, Antonio.

In: Critical Reviews in Oncology/Hematology, Vol. 50, No. 2, 05.2004, p. 101-109.

Research output: Contribution to journalArticle

@article{1b7956feb46a48689a95fcc8cce4f237,
title = "Experimental therapy of malignant mesothelioma: New perspectives from anti-angiogenic treatments",
abstract = "We reviewed the published literature of clinical studies in malignant mesothelioma (MM), including phase II as well as older single-agent and combination chemotherapy trials with more than 15 patients. While response rates exceeding 30{\%} have been achieved with established cytotoxic drugs in MM therapy, novel chemotherapeutic agents and their combinations appear more promising. This applies especially to the anti-metabolites (i.e. pemetrexed) that produced response rates of up to 45{\%} in combination with platinum compounds. Moreover, agents targeting novel proliferative and survival pathways in MM are developed to improve treatment outcomes. Here, we focused on the role of several angiogenic growth factors in MM biology and the data of MM-oriented studies on angiostatic agents tested in a phase I-II trial. It seems likely that no single treatment modality will be effective by itself. Studies that use combinations of the newer agents, including angiostatic drugs, with chemotherapy, should be conducted.",
keywords = "Anti-angiogenic agents, Mesothelioma, Therapy",
author = "Alfonso Catalano and Walter Gianni and Antonio Procopio",
year = "2004",
month = "5",
doi = "10.1016/j.critrevonc.2003.10.001",
language = "English",
volume = "50",
pages = "101--109",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Experimental therapy of malignant mesothelioma

T2 - New perspectives from anti-angiogenic treatments

AU - Catalano, Alfonso

AU - Gianni, Walter

AU - Procopio, Antonio

PY - 2004/5

Y1 - 2004/5

N2 - We reviewed the published literature of clinical studies in malignant mesothelioma (MM), including phase II as well as older single-agent and combination chemotherapy trials with more than 15 patients. While response rates exceeding 30% have been achieved with established cytotoxic drugs in MM therapy, novel chemotherapeutic agents and their combinations appear more promising. This applies especially to the anti-metabolites (i.e. pemetrexed) that produced response rates of up to 45% in combination with platinum compounds. Moreover, agents targeting novel proliferative and survival pathways in MM are developed to improve treatment outcomes. Here, we focused on the role of several angiogenic growth factors in MM biology and the data of MM-oriented studies on angiostatic agents tested in a phase I-II trial. It seems likely that no single treatment modality will be effective by itself. Studies that use combinations of the newer agents, including angiostatic drugs, with chemotherapy, should be conducted.

AB - We reviewed the published literature of clinical studies in malignant mesothelioma (MM), including phase II as well as older single-agent and combination chemotherapy trials with more than 15 patients. While response rates exceeding 30% have been achieved with established cytotoxic drugs in MM therapy, novel chemotherapeutic agents and their combinations appear more promising. This applies especially to the anti-metabolites (i.e. pemetrexed) that produced response rates of up to 45% in combination with platinum compounds. Moreover, agents targeting novel proliferative and survival pathways in MM are developed to improve treatment outcomes. Here, we focused on the role of several angiogenic growth factors in MM biology and the data of MM-oriented studies on angiostatic agents tested in a phase I-II trial. It seems likely that no single treatment modality will be effective by itself. Studies that use combinations of the newer agents, including angiostatic drugs, with chemotherapy, should be conducted.

KW - Anti-angiogenic agents

KW - Mesothelioma

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=2442430721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442430721&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2003.10.001

DO - 10.1016/j.critrevonc.2003.10.001

M3 - Article

C2 - 15157659

AN - SCOPUS:2442430721

VL - 50

SP - 101

EP - 109

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -